Immune Response News and Research

RSS

Study Uncovers Regulated Nuclear DNA Extraction in Dying Cells

Over the years, cell biology has built a detailed picture of how cells compartmentalize their internal functions. Central to this organization is the nucleus, which houses the genetic material and is separated from the cytoplasm by a robust nuclear envelope.

26 Feb 2026

New Gene-Editing Strategy to Eliminate Aggressive Cancer Cells

The initiation and severity of cancer are associated with the atypical behavior of specific genes, referred to as oncogenes. The most recognized of these changes is mutation; however, it is not the sole alteration.

9 Feb 2026

DNA Origami Vaccine Scaffolds Sharpen Immune Targeting Against HIV

One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and antibodies. In most vaccines, HIV proteins are attached to a larger protein scaffolding that mimics a virus.

6 Feb 2026

Chemistry Breakthrough Improves Gene Delivery, Reduces Side Effects

Gene therapy holds the promise of preventing and curing disease by manipulating gene expression within a patient's cells.

5 Feb 2026

How DNA Leakage into the Cytoplasm Drives Ruijs-Aalfs Syndrome

Although DNA is tightly packed and safeguarded within the cell nucleus, it remains continually at risk of damage from normal metabolic activity and external stressors such as radiation and chemical agents.

2 Feb 2026

Gut Microbial Metabolite Hippuric Acid Amplifies Immune Responses

Scientists at The Wistar Institute have identified a previously overlooked mediator in the body's response to life-threatening infections: hippuric acid, a metabolite produced when gut bacteria break down polyphenols from berries, tea, and other plant-based foods.

31 Jan 2026

Defective DNA Protein Repair Triggers Inflammation and Premature Aging

Unrepaired DNA-protein crosslinks (DPCs) – highly toxic tangles of protein and DNA – cause a process that leads to premature aging and embryonic lethality in mice.

31 Jan 2026

Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care

Natera, Inc., a global leader in cell-free DNA and precision medicine, today announced the publication of a new prospective clinical trial in Transplantation Direct. The study, which was conducted by The Ohio State University Wexner Medical Center (OSU-WMC), was initiated to explore whether donor-derived cell-free DNA (dd-cfDNA) surveillance, and specifically Prospera-guided monitoring, could reduce the number of invasive biopsies for patients following lung transplantation.

From Natera 27 Jan 2026

Cytomegalovirus can Hijack a Central 'Traffic Controller' for Immune Cells

In a major scientific breakthrough, researchers from Monash University and the Lions Eye Institute have discovered a tissue protein that acts as a central 'traffic controller' for immune cells and can be hijacked by a virus to weaken immune responses.

22 Jan 2026

Specialized Immune Cells Grown in Labs Offer Hope for Autoimmune Patients

Researchers at the University of British Columbia (UBC) have made a significant discovery regarding the cultivation of specialized immune cells, facilitating the development of readily available off-the-shelf cell therapies aimed at treating cancer, autoimmune diseases, and additional conditions.

9 Jan 2026

USU Researchers Discover CRISPR Cas12a3's Potential for Viral Protein Inhibition

Across all domains of life, immune defenses foil invading viruses by making it impossible for the viruses to replicate. Most known CRISPR systems target invading pathogens' DNA and chop it up to disable and modify genes, heading off infections at the (cellular) pass.

8 Jan 2026

Blocking Retinoic Acid Pathway Improves Dendritic Cell Anti-Tumor Function

Scientists at the Princeton University Branch of the Ludwig Institute for Cancer Research have identified novel mechanisms by which a metabolic derivative of vitamin A-all-trans retinoic acid-compromises both the body's normal anti-cancer immune response and, in a different context, the efficacy of a promising type of cancer vaccine.

6 Jan 2026